Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those with chronic gastroesophageal reflux disease (GERD) and at least 2 risk factors (eg, >50 years of age, white race, obese, tobacco smoking history).2, 3 However, providing clinicians with a tool that allows them to estimate a patients’ risk may better aid them in deciding who to screen for BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well between men with and without BE, with an area under the receiver-operating characteristic curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 vs 0.61; P < .001).4 However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice.
ASJC Scopus subject areas
Thrift, A. P., Vaughan, T. L., Anderson, L. A., Whiteman, D. C., & El-Serag, H. B. (2017). External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clinical Gastroenterology and Hepatology, 15(7), 1124-1126. https://doi.org/10.1016/j.cgh.2017.03.004